Genetic mutation of p53 and suppression of the mir-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin d signaling

Robert Borkowski, Liqin Du, Zhenze Zhao, Elizabeth McMillan, Adam Kosti, Chin Rang Yang, Milind Suraokar, Ignacio I. Wistuba, Adi F. Gazdar, John D. Minna, Michael A. White, Alexander Pertsemlidis

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related fatalities. Recent success developing genotypically targeted therapies, with potency only in well-defined subpopulations of tumors, suggests a path to improving patient survival. We used a library of oligonucleotide inhibitors of microRNAs, a class of posttranscriptional gene regulators, to identify novel synthetic lethal interactions between miRNA inhibition and molecular mechanisms in non-small cell lung cancer (NSCLC). Two inhibitors, those for miR-92a and miR-1226 , produced a toxicity distribution across a panel of 27 cell lines that correlated with loss of p53 protein expression. Notably, depletion of p53 was sufficient to confer sensitivity to otherwise resistant telomerase-immortalized bronchial epithelial cells. We found that both miR inhibitors cause sequence-specific downregulation of the miR-17-∼92 polycistron, and this downregulation was toxic only in the context of p53 loss. Mechanistic studies indicated that the selective toxicity of miR-17-∼92 polycistron inactivation was the consequence of derepression of vitamin D signaling via suppression of CYP24A1, a ratelimiting enzyme in the 1α,25-dihydroxyvitamin D3 metabolic pathway. Of note, high CYP24A1 expression significantly correlated with poor patient outcome in multiple lung cancer cohorts. Our results indicate that the screening approach used in this study can identify clinically relevant synthetic lethal interactions and that vitamin D receptor agonists may show enhanced efficacy in p53-negative lung cancer patients. Cancer Res;

Original languageEnglish (US)
Pages (from-to)666-675
Number of pages10
JournalCancer Research
Volume75
Issue number4
DOIs
StatePublished - Feb 15 2015

Fingerprint

Vitamins
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Up-Regulation
MicroRNAs
Mutation
Down-Regulation
Neoplasms
Calcitriol Receptors
Calcitriol
Poisons
Telomerase
Regulator Genes
Metabolic Networks and Pathways
Vitamin D
Oligonucleotides
Epithelial Cells
Cell Line
Survival
Enzymes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Genetic mutation of p53 and suppression of the mir-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin d signaling. / Borkowski, Robert; Du, Liqin; Zhao, Zhenze; McMillan, Elizabeth; Kosti, Adam; Yang, Chin Rang; Suraokar, Milind; Wistuba, Ignacio I.; Gazdar, Adi F.; Minna, John D.; White, Michael A.; Pertsemlidis, Alexander.

In: Cancer Research, Vol. 75, No. 4, 15.02.2015, p. 666-675.

Research output: Contribution to journalArticle

Borkowski, Robert ; Du, Liqin ; Zhao, Zhenze ; McMillan, Elizabeth ; Kosti, Adam ; Yang, Chin Rang ; Suraokar, Milind ; Wistuba, Ignacio I. ; Gazdar, Adi F. ; Minna, John D. ; White, Michael A. ; Pertsemlidis, Alexander. / Genetic mutation of p53 and suppression of the mir-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin d signaling. In: Cancer Research. 2015 ; Vol. 75, No. 4. pp. 666-675.
@article{df9e6636ccec488486071b7a8c28f2fc,
title = "Genetic mutation of p53 and suppression of the mir-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin d signaling",
abstract = "Lung cancer is the leading cause of cancer-related fatalities. Recent success developing genotypically targeted therapies, with potency only in well-defined subpopulations of tumors, suggests a path to improving patient survival. We used a library of oligonucleotide inhibitors of microRNAs, a class of posttranscriptional gene regulators, to identify novel synthetic lethal interactions between miRNA inhibition and molecular mechanisms in non-small cell lung cancer (NSCLC). Two inhibitors, those for miR-92a and miR-1226 , produced a toxicity distribution across a panel of 27 cell lines that correlated with loss of p53 protein expression. Notably, depletion of p53 was sufficient to confer sensitivity to otherwise resistant telomerase-immortalized bronchial epithelial cells. We found that both miR inhibitors cause sequence-specific downregulation of the miR-17-∼92 polycistron, and this downregulation was toxic only in the context of p53 loss. Mechanistic studies indicated that the selective toxicity of miR-17-∼92 polycistron inactivation was the consequence of derepression of vitamin D signaling via suppression of CYP24A1, a ratelimiting enzyme in the 1α,25-dihydroxyvitamin D3 metabolic pathway. Of note, high CYP24A1 expression significantly correlated with poor patient outcome in multiple lung cancer cohorts. Our results indicate that the screening approach used in this study can identify clinically relevant synthetic lethal interactions and that vitamin D receptor agonists may show enhanced efficacy in p53-negative lung cancer patients. Cancer Res;",
author = "Robert Borkowski and Liqin Du and Zhenze Zhao and Elizabeth McMillan and Adam Kosti and Yang, {Chin Rang} and Milind Suraokar and Wistuba, {Ignacio I.} and Gazdar, {Adi F.} and Minna, {John D.} and White, {Michael A.} and Alexander Pertsemlidis",
year = "2015",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-14-1329",
language = "English (US)",
volume = "75",
pages = "666--675",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Genetic mutation of p53 and suppression of the mir-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin d signaling

AU - Borkowski, Robert

AU - Du, Liqin

AU - Zhao, Zhenze

AU - McMillan, Elizabeth

AU - Kosti, Adam

AU - Yang, Chin Rang

AU - Suraokar, Milind

AU - Wistuba, Ignacio I.

AU - Gazdar, Adi F.

AU - Minna, John D.

AU - White, Michael A.

AU - Pertsemlidis, Alexander

PY - 2015/2/15

Y1 - 2015/2/15

N2 - Lung cancer is the leading cause of cancer-related fatalities. Recent success developing genotypically targeted therapies, with potency only in well-defined subpopulations of tumors, suggests a path to improving patient survival. We used a library of oligonucleotide inhibitors of microRNAs, a class of posttranscriptional gene regulators, to identify novel synthetic lethal interactions between miRNA inhibition and molecular mechanisms in non-small cell lung cancer (NSCLC). Two inhibitors, those for miR-92a and miR-1226 , produced a toxicity distribution across a panel of 27 cell lines that correlated with loss of p53 protein expression. Notably, depletion of p53 was sufficient to confer sensitivity to otherwise resistant telomerase-immortalized bronchial epithelial cells. We found that both miR inhibitors cause sequence-specific downregulation of the miR-17-∼92 polycistron, and this downregulation was toxic only in the context of p53 loss. Mechanistic studies indicated that the selective toxicity of miR-17-∼92 polycistron inactivation was the consequence of derepression of vitamin D signaling via suppression of CYP24A1, a ratelimiting enzyme in the 1α,25-dihydroxyvitamin D3 metabolic pathway. Of note, high CYP24A1 expression significantly correlated with poor patient outcome in multiple lung cancer cohorts. Our results indicate that the screening approach used in this study can identify clinically relevant synthetic lethal interactions and that vitamin D receptor agonists may show enhanced efficacy in p53-negative lung cancer patients. Cancer Res;

AB - Lung cancer is the leading cause of cancer-related fatalities. Recent success developing genotypically targeted therapies, with potency only in well-defined subpopulations of tumors, suggests a path to improving patient survival. We used a library of oligonucleotide inhibitors of microRNAs, a class of posttranscriptional gene regulators, to identify novel synthetic lethal interactions between miRNA inhibition and molecular mechanisms in non-small cell lung cancer (NSCLC). Two inhibitors, those for miR-92a and miR-1226 , produced a toxicity distribution across a panel of 27 cell lines that correlated with loss of p53 protein expression. Notably, depletion of p53 was sufficient to confer sensitivity to otherwise resistant telomerase-immortalized bronchial epithelial cells. We found that both miR inhibitors cause sequence-specific downregulation of the miR-17-∼92 polycistron, and this downregulation was toxic only in the context of p53 loss. Mechanistic studies indicated that the selective toxicity of miR-17-∼92 polycistron inactivation was the consequence of derepression of vitamin D signaling via suppression of CYP24A1, a ratelimiting enzyme in the 1α,25-dihydroxyvitamin D3 metabolic pathway. Of note, high CYP24A1 expression significantly correlated with poor patient outcome in multiple lung cancer cohorts. Our results indicate that the screening approach used in this study can identify clinically relevant synthetic lethal interactions and that vitamin D receptor agonists may show enhanced efficacy in p53-negative lung cancer patients. Cancer Res;

UR - http://www.scopus.com/inward/record.url?scp=84923166147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923166147&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-1329

DO - 10.1158/0008-5472.CAN-14-1329

M3 - Article

C2 - 25519225

AN - SCOPUS:84923166147

VL - 75

SP - 666

EP - 675

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -